Oct. 13, 2025 -- Hinge Bio, Inc., a privately-held biotechnology company engaged in the discovery and development of innovative multi-specific medicines, announced the U.S. Food and Drug Administration (“FDA”) has cleared the company’s Investigational New Drug (“IND”) application to initiate a study of HB2198 in patients with the B cell-mediated autoimmune diseases Systemic Lupus Erythematosus (“SLE”) and Lupus Nephritis (“LN”). “This IND clearance marks a significant milestone for Hinge Bio

Oct. 13, 2025 -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in rheumatoid arthritis (RA), was accepted for a late-breaking oral presentation at American College of Rheumatology (ACR) Convergence 2025 in Chicago, IL, Oct. 24 – 29, 2025. “We are honored to be selected by ACR to present our late-breaking Pha

Oct. 13, 2025 -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ficerafusp alfa in combination with pembrolizumab for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma

Presentation will cover two-year clinical efficacy, immunogenicity and safety data Data will be presented at an oral session on October 17, 2025, followed by a webinar on October 22, 2025, providing further insights into the clinical findings October 13, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present a wide range of data from its phase 2 trial with lead compound EVX-01 at the European Socie

Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC 225Ac-SSO110 achieves superior pharmacokinetics with minimal re-distribution of Actinium-225 daughter isotopes and 100% survival in preclinical studies Initial safety data from SANTANA-225 expected in 2026 Oct. 09, 2025 -- Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics company dedicated to setting new standards in cancer care, today highlighted two or

Oct. 09, 2025 -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the successful completion of the analytical validation of a cheek swab collection method for testing patients for both clinical trial usage as well as future commercial application. This major step marks a key milestone in advancing AD04 toward Food &

Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning name B-FREE, a Phase 2 trial, will commence in early November and run for approximately 12 months Oct. 09, 2025 -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease,

Oct. 09, 2025 -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced new results that demonstrate buntanetap’s ability to attenuate inflammation and improve cellular health in Alzheimer’s patients, suggesting potential disease-modifying effects beyond symptomatic relief. The analysis of patient sam

Preclinical data demonstrates that Shape’s engineered AAV5 variant, SHP-DB1, efficiently targets the NHP brain after intravenous injection and transduces >95% of neurons in the Parkinson's Disease-critical substantia nigra Shape’s novel RNAfix® gene therapy enables targeted knockdown of alpha-synuclein in mouse and NHP brain, supporting the therapeutic development of a first-in-class disease-modifying treatment for Parkinson's Disease Oct. 10, 2025 -- Shape Therapeutics, a leader in RNA-bas

Risvodetinib demonstrated to be safe and well-tolerated with preliminary clinical benefits Risvodetinib demonstrated to be the first treatment to reduce alpha-synuclein pathology, widely recognized as the underlying cause of Parkinson’s disease Blood-borne biomarkers evaluate target engagement and mechanism of action to confirm the Company’s underlying rationale for treatment Oct. 09, 2025 -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that a